Table 2

Characteristics of out-of-hospital cardiac arrest patients in treatment with a specific macrolide ≤7 days before the time of event

AzithromycinClarithromycinErythromycinRoxithromycinP value*
N (%)82 (16.0)88 (17.1)82 (16.0)262 (51.0)
Age, years (IQR)69.0 (59.6–77.4)72.1 (64.4–80.4)68.6 (52.5–77.8)72.5 (61.4–81.6)0.03
Male (%)46 (56.1)44 (50.0)37 (45.1)141 (53.8)0.46
Income group (%)
 0 (lowest income quintile)10 (12.2)8 (9.1)14 (17.1)28 (10.7)
 121 (25.6)26 (29.6)18 (22.0)66 (25.2)
 223 (28.1)28 (31.8)27 (32.9)77 (29.4)0.15
 310 (12.2)13 (14.8)14 (17.1)63 (24.1)
 4 (highest income quintile)18 (22.0)13 (14.8)9 (11.0)28 (10.6)
Comorbidity (%)
 Diabetes19 (23.2)11 (12.5)11 (13.4)33 (12.6)0.11
 Peripheral vascular disease3 (3.7)3 (3.4)3 (3.7)15 (5.7)0.83
 Previous MI5 (6.1)13 (14.8)4 (4.9)25 (9.5)0.12
 Ischaemic heart disease8 (9.8)16 (18.2)7 (8.5)30 (11.5)0.20
 Heart failure13 (15.9)17 (19.3)10 (12.2)30 (11.5)0.27
 Atrial fibrillation6 (7.3)8 (9.1)5 (6.1)26 (9.9)0.76
 COPD24 (29.3)20 (23.6)15 (18.3)62 (23.7)0.43
 Cancer4 (4.9)11 (12.5)7 (8.5)21 (8.0)0.36
 Depression5 (6.1)5 (5.7)1 (1.2)4 (1.5)0.04
 Any psychiatric disease13 (15.9)12 (13.6)10 (12.2)22 (8.4)0.21
 Charlson score (IQR)1 (0–2)1 (0–2)0 (0–1)1 (0–2)0.16
Concomitant pharmacotherapy (%)
 Lipid-lowering drugs13 (15.9)10 (11.4)9 (11.0)37 (14.1)0.74
 Loop diuretics30 (36.6)34 (38.6)21 (25.6)80 (30.5)0.23
 Beta-blockers17 (20.7)19 (21.6)16 (19.5)45 (16.8)0.71
 ACE inhibitors22 (26.8)28 (31.8)14 (17.1)58 (22.1)0.11
 Vitamin K antagonists5 (6.1)3 (3.4)2 (2.4)19 (7.3)0.33
 Antiplatelets0 (0.0)1 (1.1)1 (1.2)9 (3.4)0.28
 Antipsychotics12 (14.6)10 (11.4)10 (12.2)21 (8.0)0.31
 Antidepressants17 (20.7)20 (22.7)11 (13.4)61 (23.3)0.29
 Anxiolytics22 (26.8)30 (34.1)21 (25.6)82 (31.3)0.56
  • Dichotomous variables given in absolute numbers and percentages.

  • Continuous variables given in medians and IQR.

  • *P value for differences between roxithromycin, erythromycin, clarithromycin and azithromycin.

  • COPD, chronic obstructive pulmonary disease; MI, myocardial infarction.